EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY-NC 4.0

Real‐world comparative effectiveness and safety of Pertuzumab in patients with HER2+ metastatic breast cancer: A pan‐Canadian population‐based cohort study

Caroline E Muñoz, Wei Fang Dai, Winson Y Cheung, Claire de Oliveira, Reka E Pataky, Philip Q Ding, David A Tran, Zeb Aurangzeb, Chenthila Nagamuthu, Ning Liu, Lynn Lethbridge, Carol McClure und 20 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35448 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Caroline E Muñoz und 31 weiteren Autor:innen. Beteiligte Einrichtung: Ontario Health (CCO), Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We assessed the comparative effectiveness and safety of pertuzumab plus trastuzumab and chemotherapy versus trastuzumab and chemotherapy for patients with HER2+ metastatic breast cancer (mBC) in Canada. We conducted a population‐based retrospective study of patients receiving first‐line treatment for mBC across eight Canadian provinces. Patients receiving trastuzumab and chemotherapy were historical comparators, and patients receiving pertuzumab plus trastuzumab and chemotherapy were the treatment group. Patients were followed until death or up to 5 years following the start of treatment (maximum follow‐up to December 31, 2019). The primary outcome was overall survival (OS). One‐year cumulative incidence and RDs were calculated for safety outcomes including hospitalization, emergency department visits, febrile neutropenia, and cardiac‐related events. Propensity score matching (PSM) and inverse‐probability of treatment weighting (IPTW) were applied within provinces. Individual provincial survival estimates were pooled using random effects meta‐analysis. 3063 patients who received first‐line treatment for mBC were identified. Median OS was higher among treatment patients compared to comparator patients in most provinces. Pertuzumab was associated with a statistically significantly lower risk of mortality (pooled HRs, PSM: 0.65, 95%CI: 0.57–0.74; IPTW: 0.65, 95% CI: 0.61–0.70). The treatment group had a lower risk of hospitalization compared to the comparator group (pooled RD: −0.05, 95% CI: [−0.09]–[−0.01]). No difference in 1‐year cumulative incidence of cardiac‐related events was identified between groups. Pertuzumab use in practice was associated with statistically significant improved survival without apparent safety concerns among patients with mBC. Real‐world evaluations allow for assessments of publicly funded treatments to inform funding policies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleCanadaMiddle AgedRetrospective StudiesErb-b2 Receptor Tyrosine KinasesTrastuzumabAgedAdultTreatment Outcome

Stichwörter der Autor:innen

effectivenessoncologyreal‐world datareal‐world evidencesafety

Substanzen

Antibodies, Monoclonal, HumanizedErb-b2 Receptor Tyrosine KinasesTrastuzumabpertuzumabERBB2 protein, human

Autor:innen und Institutionen

  • Ontario Health (CCO), Toronto, Ontario, Canada.
  • Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario, Canada.
  • Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • University of Calgary, Calgary, Alberta, Canada.
  • Oncology Outcomes (O2) Research Program, Calgary, Alberta, Canada.
  • ICES, Toronto, Ontario, Canada.

ORCID-Profile: Stuart Peacock, Rebecca E Mercer, Kelvin K W Chan

Förderung

  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Muñoz, C. E., Dai, W. F., Cheung, W. Y., de Oliveira, C., Pataky, R. E., Ding, P. Q., Tran, D. A., Aurangzeb, Z., Nagamuthu, C., Liu, N., Lethbridge, L., McClure, C., Vriends, K., Xiong, H., Folkins, C., Somayaji, C., Peacock, S., Alvi, R., Turner, D., …, & CanREValue Collaboration (2025). Real‐world comparative effectiveness and safety of Pertuzumab in patients with HER2+ metastatic breast cancer: A pan‐Canadian population‐based cohort study. International Journal of Cancer. https://doi.org/10.1002/ijc.35448

Vancouver

Muñoz CE, Dai WF, Cheung WY, de Oliveira C, Pataky RE, Ding PQ, et al. Real‐world comparative effectiveness and safety of Pertuzumab in patients with HER2+ metastatic breast cancer: A pan‐Canadian population‐based cohort study. International Journal of Cancer. 2025. doi:10.1002/ijc.35448

BibTeX
@article{Muoz2025,
  author = {Muñoz, Caroline E and Dai, Wei Fang and Cheung, Winson Y and de Oliveira, Claire and Pataky, Reka E and Ding, Philip Q and Tran, David A and Aurangzeb, Zeb and Nagamuthu, Chenthila and Liu, Ning and Lethbridge, Lynn and McClure, Carol and Vriends, Kim and Xiong, Hui and Folkins, Chris and Somayaji, Chandy and Peacock, Stuart and Alvi, Riaz and Turner, Donna and O'Conaill, Carrie and McDonald, Ted and Urquhart, Robin and Kendell, Cynthia and Dowden, Jeff and Strumpf, Erin and Denburg, Avram and Beca, Jaclyn M and Mercer, Rebecca E and Tadrous, Mina and Takhar, Pam and Chan, Kelvin K W and CanREValue Collaboration, CanREValue Collaboration},
  title = {Real‐world comparative effectiveness and safety of Pertuzumab in patients with HER2+ metastatic breast cancer: A pan‐Canadian population‐based cohort study},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35448}
}
Kostenlos starten →